BridgeBio Pharma (BBIO) has announced that the Committee for Medicinal Products for Human Use (CHMP) has given a positive recommendation for marketing authorization of acoramidis. This medication is intended for treating adult patients with cardiomyopathy due to either wild-type or variant transthyretin amyloidosis. A final decision from the European Commission is anticipated in the upcoming months. Acoramidis received approval from the FDA on November 22, 2024.
Since March 2024, BridgeBio has been collaborating with Bayer on acoramidis. BridgeBio has the marketing rights in the United States, while Bayer is responsible for marketing in Europe. With the European Commission's approval pending, Bayer aims to introduce acoramidis to the European market in the first half of 2025.
The material has been provided by InstaForex Company - www.instaforex.com
Since March 2024, BridgeBio has been collaborating with Bayer on acoramidis. BridgeBio has the marketing rights in the United States, while Bayer is responsible for marketing in Europe. With the European Commission's approval pending, Bayer aims to introduce acoramidis to the European market in the first half of 2025.
The material has been provided by InstaForex Company - www.instaforex.com